^
    Back
    Association details:
    Biomarker:ERCC5 overexpression
    Cancer:Small Cell Lung Cancer
    Drug:berzosertib (M6620) (ATR inhibitor) +
    Zepzelca (lurbinectedin) (Alkylating agent, Apoptosis stimulant, RNA polymerase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    EMBO Mol Med
    Title:

    ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer

    Published date:
    07/25/2023
    Excerpt:
    Increased ERCC5/XPG expression significantly correlated with improved combination efficacy, while higher SLFN11 expression trended toward increased combination efficacy...
    DOI:
    https://doi.org/10.15252/emmm.202217313